{
  "id": "61f5914e882a024a1000000d",
  "type": "factoid",
  "question": "Aducanumab can be used for treatment of which disease?",
  "ideal_answer": "Aducanumab is approved for treatment of Alzheimer's disease.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34506904",
    "http://www.ncbi.nlm.nih.gov/pubmed/34234067",
    "http://www.ncbi.nlm.nih.gov/pubmed/34741884",
    "http://www.ncbi.nlm.nih.gov/pubmed/34550687",
    "http://www.ncbi.nlm.nih.gov/pubmed/34263875",
    "http://www.ncbi.nlm.nih.gov/pubmed/29686315",
    "http://www.ncbi.nlm.nih.gov/pubmed/34539340",
    "http://www.ncbi.nlm.nih.gov/pubmed/34697913",
    "http://www.ncbi.nlm.nih.gov/pubmed/34650610",
    "http://www.ncbi.nlm.nih.gov/pubmed/34535787",
    "http://www.ncbi.nlm.nih.gov/pubmed/29067304",
    "http://www.ncbi.nlm.nih.gov/pubmed/34585212",
    "http://www.ncbi.nlm.nih.gov/pubmed/34827546",
    "http://www.ncbi.nlm.nih.gov/pubmed/33836798",
    "http://www.ncbi.nlm.nih.gov/pubmed/34324167",
    "http://www.ncbi.nlm.nih.gov/pubmed/34554383",
    "http://www.ncbi.nlm.nih.gov/pubmed/27582220",
    "http://www.ncbi.nlm.nih.gov/pubmed/34366359",
    "http://www.ncbi.nlm.nih.gov/pubmed/34554982",
    "http://www.ncbi.nlm.nih.gov/pubmed/29181491",
    "http://www.ncbi.nlm.nih.gov/pubmed/33135381"
  ],
  "snippets": [
    {
      "text": "We highlight additional evidence consistent with the underwhelming efficacy of A\u03b2 oligomer-lowering agents, such as aducanumab, and of antioxidants, such as vitamin E, versus the so far isolated case report that DNase-I treatment for 2 months resulted in a severe AD patient's Mini-Mental State Exam score increasing from 3 to 18, reversing his diagnosis to moderate AD, according to the Mini-Mental State Exam.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34506904",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "On 7 June 2021, aducanumab was granted accelerated approval for the treatment of Alzheimer disease (AD) by the FDA on the basis of amyloid-lowering effects considered reasonably likely to confer clinical benefit. This decision makes aducanumab the first new drug to be approved for the treatment of AD since 2003 and the first drug to ever be approved for modification of the course of AD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34535787",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "While the vast majority of immunotherapies have been developed for A\u03b2 and tested in Alzheimer's disease, the field has progressed to targeting other proteins including \u03b1Syn. Despite showing some remarkable results in animal models, immunotherapies have largely failed final stages of clinical trials to date, with the exception of Aducanumab recently licenced in the US by the FDA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34539340",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The recent approval of aducanumab for Alzheimer's disease has heightened the interest in therapies targeting the amyloid hypothesis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34550687",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aducanumab (Aduhelm), the first new drug to treat Alzheimer's disease since 2003, has received accelerated approval from the Food and Drug Administration (FDA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34554982",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aducanumab is approved in the United States for the treatment of mild cognitive impairment or mild-dementia stage of AD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34650610",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "On the one hand, aducanumab is the first drug to be approved for the treatment of the disease since 2003 and is the first drug to act on the alleged pathophysiological mechanisms of AD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34263875",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In June 2021, aducanumab received its first approval in the USA for the treatment of Alzheimer's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34324167",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "On June 7, 2021, the US Food and Drug Administration (FDA) approved aducanumab, a monoclonal amyloid targeting \u03b2-amyloid, for the treatment for Alzheimer's disease (AD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34263875",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aducanumab, a human monoclonal antibody that preferentially binds to aggregated amyloid-\u03b2 to reduce the number of amyloid plaques and slow disease progression, was approved to treat AD by the US Food and Drug Administration on June 7, 2021.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34234067",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The regulatory approval of the disease-modifying agent aducanumab has brought more attention to the complexity of the diagnosis, evaluation, and treatment of AD and the difficult decisions payers and policy makers will face over the next few years as innovation continues in this space.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34554383",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Based on the reduction of amyloid \u03b2 plaques, US FDA has recently approved Aducanumab as a disease modifying treatment for Alzheimer's disease (AD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34741884",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aducanumab is a human immunoglobulin G1 anti-amyloid beta (A\u03b2) antibody currently being evaluated for potential treatment of patients with early Alzheimer's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34697913",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34366359",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27582220",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Aducanumab, a human-derived antibody targeting amyloid-\u03b2 (A\u03b2), is in Phase 3 clinical trials for the treatment of Alzheimer's disease. Bi",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29686315",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "2021, aducanumab received its first approval in the USA for the treatment of Alzheimer's disease. Accordin",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34324167",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aducanumab, a human monoclonal antibody, was approved in June of 2021 as the first disease-modifying treatment for Alzheimer's disease by the United States Food and Drug Administration (U.S. FDA). A",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34827546",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aducanumab (Aduhelm), the first new drug to treat Alzheimer's disease since 2003, has received accelerated approval from the Food and Drug Administration (FDA).Thi",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34554982",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Based on the reduction of amyloid \u03b2 plaques, US FDA has recently approved Aducanumab as a disease modifying treatment for Alzheimer's disease (AD). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34741884",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "On June 7, 2021, the US Food and Drug Administration (FDA) approved aducanumab, a monoclonal amyloid targeting \u03b2-amyloid, for the treatment for Alzheimer's disease (AD). This ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34263875",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article summarizes the milestones in the development of aducanumab leading to this first approval for Alzheimer's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34324167",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aducanumab, a human-derived antibody targeting amyloid-\u03b2 (A\u03b2), is in Phase 3 clinical trials for the treatment of Alzheimer's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29686315",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: Aducanumab (BIIB037), a human monoclonal antibody selective for aggregated forms of amyloid beta, is being investigated as a disease-modifying treatment for Alzheimer's disease (AD).METHODS: This randomized, double-blind, placebo-controlled single ascending-dose study investigated the safety, tolerability, and pharmacokinetics (PK) of aducanumab in patients wi",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29067304",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinical Development of Aducanumab, an Anti-A\u03b2 Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29181491",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "These results justify further development of aducanumab for the treatment of AD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27582220",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Aducanumab is an anti-amyloid-\u03b2 (A\u03b2) antibody that achieved reduced amyloid pathology in Alzheimer's disease (AD) trials; however, it is controversial whether it also improved cognition, which has been suggested would require a sufficiently high cumulative dose of the antibody i",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33836798",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Aducanumab has been approved by the US Food and Drug Administration for treatment of Alzheimer's disease (AD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34585212",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "[Aducanumab and Alzheimer's disease: a critical reflection.]",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34263875",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Aducanumab's efficacy as a treatment for the cognitive dysfunction in Alzheimer's disease cannot be proven by clinical trials with divergent outcomes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33135381",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Alzheimer's disease"
}